Cardiovascular risk

Assessing cardiovascular risk

Optimal cardiovascular risk assessment allows doctors to adjust treatment in high-risk patients in an early stage.

Cardiovascular risk in renal disease

Patients with chronic kidney disease have greatly increased risks of cardiovascular events and cardiovascular deaths. Furthermore, when events occur, their morbidity and mortality is higher. It is known that conventional cardiovascular risk scores such as Framingham tables, significantly underestimate the risk of cardiovascular disease in patients with chronic kidney disease.
 
Finding patients with an increased cardiovascular risk allows physicians to adjust the treatment for these patients in an early phase. The AGE Reader has been shown to identify renal patients with an increased cardiovascular risk.
 

The AGE Reader has been tested extensively in renal disease, which led to the following important conclusions:

  • Skin AF is an independent predictor of cardiovascular disease associated mortality in hemodialysis patients.
  • Skin AF is a strong and independent predictor of mortality and chronic graft loss in renal transplant recipients.
  • Skin AF correlates to arterial elasticity and diastolic function in both hemodialysis and peritoneal dialysis patients.
 
Recommended reading: 

Read more about cardiovascular risk in atherosclerosis

More Information
Request informations

Would you like to learn more about our products? Request any information you wish to receive here.

AGE Reader mu
Non-invasive cardiovascular risk assessment
The AGE Reader mu is the next generation AGE Reader that combines a high measurement quality standard with an innovative design, at a reduced pricelevel. The AGE Reader mu is a perfect tool for diabetologists and family doctors.
Read more »
About the company

Find information about Diagnoptics.

Information for patients

Find information about Diagnoptics' products and Advanced Glycation Endproducts.

Information for professionals

Find information about Advanced Glycation Endproducts, the AGE measurement and the clinical validation.a